ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Recent advances in diagnostic and therapeutic approaches for pulmonary enteric adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Prognostic factors for resected invasive mucinous lung adenocarcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (JCO precision oncology · 2025Trial
- Efficacy of Zenocutuzumab inThe New England journal of medicine · 2025Trial
- Invasive mucinous adenocarcinoma of the lung: integrating molecular landscape, imaging phenotypes, and translational therapeutic strategies.Translational lung cancer research · 2026Review
- NRG1 fusions in non-small cell lung cancer: biology, diagnostics, and emerging HER2/HER3 therapies-a narrative review.Translational lung cancer research · 2026Review
- CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma.Diagnostic pathology · 2026Article
- The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2026Article
- HNF4α controls growth, identity, and KRAS inhibitor response in invasive mucinous adenocarcinoma of the lung.The Journal of clinical investigation · 2026Article
- Cellular plasticity as a therapeutic vulnerability: HNF4α is a key target in lung adenocarcinoma.The Journal of clinical investigation · 2026Article
- Molecular characteristics, clonal relatedness and surgical outcomes of pulmonary mixed invasive mucinous and non-mucinous adenocarcinoma: a retrospective cohort study.Molecular biomedicine · 2026Article
- NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer.Journal of the National Cancer Institute · 2026Article
- Clinical characteristics, prognosis, and nomograms for lung invasive mucinous adenocarcinoma with distant metastasis: a population-based study.Translational cancer research · 2026Article
- Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review.Frontiers in oncology · 2026Article
- Bilateral pulmonary cavitary mucinous adenocarcinoma in an immunocompetent patient: a case report and literature review.BMC pulmonary medicine · 2025Review
- Lung metastases.Nature reviews. Disease primers · 2025Review
- Comprehensive identification of NRG1 fusions in 25,203 patients with solid tumors.NPJ precision oncology · 2025Article
- Survival Outcomes of Lung Adenocarcinoma With Intestinal Differentiation in the Era of Immunotherapy.JTO clinical and research reports · 2025Article
- Emerging importance of HER3 in tumorigenesis and cancer therapy.Nature reviews. Clinical oncology · 2025Review
- Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 1 institution in 1 country.
Funding
Abstract
purposeInvasive mucinous adenocarcinoma (IMA) is a unique subtype of lung adenocarcinoma, characterized genomically by frequent EXPERIMENTAL
designA total of 200 IMAs were analyzed by 410-gene DNA next-generation sequencing (MSK-IMPACT;
resultsCombined MSK-IMPACT and MSK-Fusion testing identified mutually exclusive driver alterations in 96% of IMAs, including
conclusionsThis is the largest molecular study of IMAs to date, where we demonstrate the presence of a major oncogenic driver in nearly all cases. This study is the first to document more aggressive characteristics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.